GT Biopharma Inc (GTBP) — Titan Protect Analysis

GTBP

GT Biopharma Inc

Healthcare · ·

$0.44

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$17M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-0.04

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-921.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$3.00

+588% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About GT Biopharma Inc

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumo

https://www.gtbiopharma.com

Country: United States Employees: 1 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.301

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0487

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.674

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-62.6%

Historical annualised return based on price data

Max Drawdown

-92.8%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.64

Less volatile than the market — more defensive

52W High

$3.85

89% below the year high

52W Low

$0.26

67% above the year low

Avg Volume

1,211,515

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-6.46

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-9,982,000

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-37,042,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$3.00

Target Median

$3.00

Target Low

$3.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go